USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $-0.91 | $-0.83 | $-0.63 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $0.00 | $0.00 | $0.00 |
Akero Therapeutics's next earnings date is Wednesday, Nov 10, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-1.09 | $-1.59 | $-0.79 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 5 | $-3.11 | $-3.56 | $-2.80 |
| Dec 2022 | 6 | $-3.69 | $-4.46 | $-3.22 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-1.11 | $-1.11 | $-1.11 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-3.15 | $-3.13 | $-3.13 |
| Dec 2022 | 0 / 0 | $-3.63 | $-3.49 | $-3.49 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $0.00 | $0.00 | $0.00 |
| Dec 2022 | 6 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $-0.91 | - | - |
| Aug 13, 2021 | Jun 2021 | $-0.71 | $-0.83 | -17.61% |
| May 13, 2021 | Mar 2021 | $-0.94 | $-0.43 | 54.06% |
| Mar 16, 2021 | Dec 2020 | $-0.60 | $-0.86 | -44.42% |
| Nov 12, 2020 | Sep 2020 | $-0.67 | $-0.63 | 6.11% |
| Aug 12, 2020 | Jun 2020 | $-0.62 | $-0.57 | 7.72% |
| May 13, 2020 | Mar 2020 | $-0.61 | $-0.42 | 31.15% |
| Mar 16, 2020 | Dec 2019 | $-0.58 | $-0.55 | 5.97% |
| Nov 12, 2019 | Sep 2019 | $-0.43 | $-0.56 | -30.69% |
| Aug 12, 2019 | Jun 2019 | $-0.36 | $-0.26 | 28.51% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 16, 2021 | Dec 2020 | $-2.21 | $-2.48 | - |
| Mar 16, 2020 | Dec 2019 | $-2.81 | $-1.37 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $0.00 | - | - |
| Aug 13, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 13, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 16, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Nov 12, 2020 | Sep 2020 | $0.00 | $0.00 | - |
| Aug 12, 2020 | Jun 2020 | $0.00 | $0.00 | - |
| May 13, 2020 | Mar 2020 | $0.00 | $0.00 | - |
| Mar 16, 2020 | Dec 2019 | $0.00 | $0.00 | - |
| Nov 12, 2019 | Sep 2019 | $0.00 | $0.00 | - |
| Aug 12, 2019 | Jun 2019 | $0.00 | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 16, 2021 | Dec 2020 | $0.00 | $0.00 | - |
| Mar 16, 2020 | Dec 2019 | $0.00 | $0.00 | - |
AKRO's next earnings date is Wednesday, Nov 10, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 6 analysts, the average EPS estimation for Akero Therapeutics's next quarterly earnings is $-0.91, with a low EPS estimation of $-1.15, and a high estimation of $-0.75.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.92, the last 2 month trend is $-0.83, and the 3 month trend is $-0.83.
Based on 4 analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.
Akero Therapeutics's previous earnings date was Aug 13, 2021 for its fiscal quarter ended Jun 30, 2021.
AKRO's earnings per share (EPS) was $-0.83, missing the consensus analysts forecast of $-0.71 by -17.61%.
The EPS was lower than the previous fiscal quarter (Mar 2021) by 93.02%, and lower than the same period a year before (Jun 2020) by 45.61%.
Revenues were $0.00.
The company reported a net income of $-28.93M.Free cash flow for the quarter was $-20.03M , compared to $-18.35M last quarter and $-22.58M a year before.
AKRO ended the quarter with $1.64M in total debt, a decrease of -8.87% compared to the previous quarter.
Akero Therapeutics's previous annual earnings date was Mar 16, 2021 for its fiscal year ended Dec 31, 2020.
AKRO's earnings per share (EPS) was $-2.48, missing the consensus analysts forecast of $-2.21 by 12.22% , and lower than the previous year's EPS (Dec 2019) by 81.02%.
Revenues were $0.00.
The company reported a net income of $-79.21M.
Akero Therapeutics reported a free cash flow of $-70.95M for its fiscal year, compared to $-35.63M a year ago.
The company ended the fiscal year with $1.81M in total debt. lala
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
